Skip to main content

Table 1 Baseline characteristics of study participants (n = 329)

From: Effects of body mass index and serum albumin on overall survival in patients with cancer undergoing pancreaticoduodenectomy: a single-center retrospective cohort study

Variables

Total (n = 329)

Group 1 (n = 258)

Group 2 (n = 71)

P-value

Group I (n = 89)

Group II (n = 240)

P-value

Age (years)

65.0 (56.0–71.0)

65.0 (57.0–71.0)

64.0 (54.0–69.0)

0.131

69.0 (61.5–75.5)

64.0 (56.0–69.0)

0.000

Sex (n/%)

0.297

 

0.356

 Male

186 (56.5)

142 (55.0)

44 (62.0)

54 (60.7)

132 (55.0)

 Female

143 (43.5)

116 (45.0)

27 (38.0)

35 (39.3)

108 (45.0)

Smoking history (n/%)

63 (19.1)

52 (20.2)

11 (15.5)

0.377

15 (16.9)

48 (20.0)

0.519

Alcohol history (n/%)

40 (12.2)

33 (12.8)

7 (9.9)

0.503

31 (12.9)

9 (10.1)

0.489

ASA class (n/%)

0.219

 

0.000

 I

9 (2.7)

5 (1.9)

4 (5.6)

1 (1.1)

8 (3.3)

 II

259 (78.7)

206 (79.8)

53 (74.6)

58 (65.2)

201 (83.8)

 III

61 (18.5)

3 (18.2)

14 (19.7)

30 (33.7)

31 (12.9)

Diabetes (n/%)

75 (22.8)

55 (21.3)

20 (28.2)

0.223

24 (27.0)

51 (21.3)

0.272

HbA1c (%)

5.8 (5.3–6.7)

5.7 (5.3–6.5)

6.2 (5.4–6.8)

0.106

5.8 (5.2–7.8)

5.8 (5.3–6.6)

0.618

Hypertension (n/%)

115 (35.0)

87 (33.7)

28 (39.4)

0.371

31 (34.8)

84 (35.0)

0.977

CHD (n/%)

8 (2.4)

4 (1.6)

4 (5.6)

0.070

2 (2.2)

6 (2.5)

1.000

ALT (U/L)

107.8 (31.0–243.6)

108.3 (28.4–253.5)

107.3 (38.4–233.2)

0.723

110.5 (48.6–172.0)

105.2 (22.0–275.6)

0.833

CRP (mg/L)

5.8 (2.8–13.8)

5.7 (2.8–12.9)

6.8 (2.9–15.3)

0.574

8.4 (5.5–26.1)

4.8 (2.4–11.8)

0.000

CEA (ng/ml)

3.2 (2.2–4.8)

3.3 (2.2–5.1)

3.1 (2.1–4.5)

0.313

3.4 (2.5–5.1)

3.2 (2.1–4.7)

0.279

CA-199 (U/ml)

115.6 (35.3–367.0)

122.1 (34.7–423.4)

100.5 (39.7–321.4)

0.601

168.9 (42.9–718.5)

108.6 (31.7–218.3)

0.022

BMI (kg/m2)

22.8 (20.8–24.8)

22.0 (20.3–23.4)

26.4 (25.6–27.3)

0.000

22.5 (20.5–24.4)

22.9 (21.0–24.8)

0.517

Albumin (g/L)

37.4 (34.5–40.5)

37.4 (34.4–40.2)

38.8 (34.5–41.3)

0.205

33.1 (30.7–33.9)

39.3 (37.0–41.8)

0.000

TB (mmol/L)

81.5 (15.0–200.7)

81.7 (14.8–200.1)

77.7 (16.3–201.9)

0.454

153.8 (58.9–288.5)

37.4 (12.8–165.1)

0.000

Cancer stage (n/%)

0.141

 

0.009

 I

118 (35.9)

96 (37.2)

22 (31.0)

43 (48.3)

75 (31.3)

 II

161 (48.9)

128 (49.6)

33 (46.5)

32 (36.0)

129 (53.8)

 III

50 (15.2)

34 (13.2)

16 (22.5)

14 (15.7)

36 (15.0)

Location (n/%)

0.076

 

0.009

 Pancreas

229 (69.6)

181 (70.2)

48 (67.6)

50 (56.2)

179 (74.6)

 Ampulla of Vater

27 (8.2)

22 (8.5)

5 (7.0)

12 (13.5)

15 (6.3)

 Duodenum

34 (10.3)

30 (11.6)

4 (5.6)

14 (15.7)

20 (8.3)

 Common bile duct

39 (11.9)

25 (9.7)

14 (19.7)

13 (14.6)

26 (10.8)

  1. Group 1, BMI < 25 kg/m2; group 2, BMI ≥ 25 kg/m2; group I, serum albumin < 35 g/L; group II, serum albumin ≥ 35 g/L
  2. ALT alanine transaminase, ASA American Society of Anesthesiologists, BMI body mass index, CA-199 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CHD coronary heart disease, CRP C-reactive protein, TB total bilirubin